Renal Disease
Disease State Hub
Featured
03/05/2024
In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
03/05/2024
02/26/2024
Ronald N. Rubin, MD1,2, Adam M. Rubin MD3
Ronald N. Rubin, MD1,2, Adam M. Rubin MD3
A 58-year-old man is brought to the office by his family for worsening signs and symptoms of his known, pre-existing cirrhosis of the liver.
02/26/2024
01/29/2024
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
01/29/2024
Interactive Features
01/17/2020
How well do you know the Endocrine Society's clinical practice guideline on the management of primary aldosteronism? Test your knowledge in our latest quiz.
01/17/2020
Clinical Insights
03/05/2024
In this article, Michael J Bloch, MD, discusses the usage of RAS-blocking agents, slowing the progression of end-stage renal disease, and reducing cardiovascular events in patients with advanced kidney...
03/05/2024
01/24/2024
In part 1 of this 2-part episode, James Matera, DO, FACOI, speaks about the role, benefits, and challenges of urgent-start peritoneal dialysis in adults and children with chronic kidney disease...
01/24/2024
12/20/2023
In this video, James Matera, DO, discusses the management of patients with primary hyperoxaluria (PH), including dietary modifications, hepatic and/or kidney transplantation, RNA interference agents,...
12/20/2023
03/23/2023
In part 2 of this 2-part episode, James Matera, DO, FACOI, speaks about the infrastructure required for urgent-start peritoneal dialysis (PD) and the urgent-start PD clinical pathway from patient...
03/23/2023
10/29/2022
In this podcast, Sri Banerjee, MD, PhD, MPH, MAS, speaks about his research on the association between food insecurity, cardiorenal syndrome, and all-cause mortality among low-income adults in the United...
10/29/2022